Dihydrocodeine 3 mg/BPM 4 mg/Phenyleph HCl 7.5 mg/5 mL Liquid
Each 5 mL (one teaspoonful) for oral administration contains:Dihydrocodeine bitartrate* .......................................... 3 mg*(WARNING-May be habit forming)Brompheniramine maleate .......................................... 4 mgPhenylephrine hydrochloride .................................... 7.5 mg Dihydrocodeine 3 mg/BPM 4 mg/Phenyleph HCl 7.5 mg/5 mL Liquid also contains: citric acid, glycerin, grape flavor, propylene glycol, purified water, sodium citrate, sodium saccharin, sorbitol. Dihydrocodeine bitartrate is an antitussive with the chemical name Morphinan-6-ol,4,5-epoxy-3-methoxy-17-methyl-, (5α,6α)-2,3-dihydroxybutanedioate (1:1) (salt).

Brompheniramine maleate is an antihistamine having the chemical name, 2-Pyridinepropanamine,γ-(4-bromophenyl)-N, N-dimethyl-, (±)-,(Z)-2-butenedioate (1:1).

Phenylephrine hydrochloride is an orally effective nasal decongestant. Chemically it is (–)-m-Hydroxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride.

Dihydrocodeine is a semi-synthetic narcotic analgesic related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system and organs with smooth muscle components. Brompheniramine maleate is an alkylamine type antihistamine. This group of antihistamines is among the most active histamine antagonists and is generally effective in relatively low doses. The drugs are not so prone to produce drowsiness and are among the most suitable agents for daytime use, but a significant proportion of patients do experience this effect. Phenylephrine HCl is a sympathomimetic, which acts predominately on alpha-receptors and has little action on beta-receptors. It therefore functions as an oral nasal decongestant with minimal CNS stimulation.

Dihydrocodeine 3 mg/BPM 4 mg/Phenyleph HCl 7.5 mg/5 mL Liquid is indicated to control cough and provide for temporary relief from congestion associated with the upper respiratory tract.

This product should not be administered to patients with hypersensitivity to dihydrocodeine, codeine, or any other component of this product, or in any condition where opioids are contraindicated including: significant respiratory depression (in unmonitored settings or in the absence of resuscitation equipment), acute or severe bronchial asthma, hypercapnia, or paralytic ileus. Antihistamines and sympathomimetics are contraindicated in patients receiving antihypertensive or antidepressant drugs containing monoamine oxidase (MAO) inhibitors. Antihistamines should not be used to treat lower respiratory tract symptoms or be given to premature or newborn infants. Sympathomimetic agents are contraindicated in patients with severe hypertension, severe coronary artery disease, patients with narrow angle glaucoma, bronchial asthma, urinary retention, peptic ulcer, and during an asthma attack. This product is contraindicated in women who are pregnant.

General At dosages higher than the recommended dose, nervousness, dizziness, or sleeplessness may occur. Antihistamines may cause excitability, especially in children. Dihydrocodeine 3 mg/BPM 4 mg/Phenyleph HCl 7.5 mg/5 mL Liquid should be used with caution in the elderly (60 years and older), as they are more likely to exhibit adverse reactions. Specia